公开(公告)号：US20250127730A1

公开(公告)日：2025-04-24

申请号：US18984062

申请日：2024-12-17

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN

IPC: A61K31/045 ,  A61K9/00 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4188 ,  A61K31/4745 ,  A61K39/00 ,  A61K39/395 ,  A61K40/11 ,  A61K40/31 ,  A61K40/42 ,  A61K45/06 ,  A61P35/00 ,  C07K14/705 ,  C07K16/28 ,  C07K16/42 ,  C12N5/0783 ,  C12N5/16 ,  C12P5/00

Abstract: The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be administered by intraarterial injection. The CNS cancer can be a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas.

公开(公告)号：US20240216293A1

公开(公告)日：2024-07-04

申请号：US18557650

申请日：2022-04-28

Applicant: NEONC TECHNOLOGIES, INC

Inventor： Thomas CHEN

IPC: A61K31/045 ,  A61K9/00 ,  A61K31/195 ,  A61P25/16

CPC classification number: A61K31/045 ,  A61K9/0043 ,  A61K31/195 ,  A61P25/16

Abstract: The present application presents compositions and methods for the intranasal administration of perillyl alcohol and L-Dopa to a patient in need of treatment for Parkinson's Disease. The compositions and methods of the present application enhance the entry of L-Dopa into the brain of the patient suffering from Parkinson's Disease

公开(公告)号：US20220363619A1

公开(公告)日：2022-11-17

申请号：US17749293

申请日：2022-05-20

Applicant: NEONC Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPPALI

IPC: C07C29/92 ,  C07C67/14 ,  C07C201/12 ,  A61K31/045 ,  C07C29/78 ,  C07C29/88 ,  C07C201/16 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07C29/86

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

公开(公告)号：US20200078355A1

公开(公告)日：2020-03-12

申请号：US16384534

申请日：2019-04-15

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPALLI

IPC: A61K31/495 ,  A61K47/54 ,  A61K9/00 ,  C07C33/14 ,  C07B59/00 ,  A61K31/4015 ,  A61K31/045 ,  A61K31/4188 ,  C07D487/04 ,  C07D231/12 ,  C07D207/26 ,  A61N5/10 ,  A61K45/06 ,  A61K31/415

Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

公开(公告)号：US20190275031A1

公开(公告)日：2019-09-12

申请号：US16123729

申请日：2018-09-06

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPALLI

IPC: A61K31/495 ,  A61K47/54 ,  A61K31/415 ,  A61K9/00 ,  C07C33/14 ,  A61K45/06 ,  C07B59/00 ,  A61K31/045 ,  A61K31/4015 ,  A61K31/4188 ,  C07D487/04 ,  C07D231/12 ,  C07D207/26 ,  A61N5/10

Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

公开(公告)号：US20190167669A1

公开(公告)日：2019-06-06

申请号：US16313388

申请日：2017-06-30

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN

IPC: A61K31/495 ,  A61N5/10 ,  C07D231/12 ,  A61K31/4188 ,  A61K47/54 ,  C07B59/00 ,  A61K31/4015 ,  A61K9/00 ,  A61K31/045 ,  A61K31/415 ,  C07D207/26 ,  C07C33/14 ,  C07D487/04 ,  A61K45/06

Abstract: The present methods treat neurofibromatosis by a administering to a subject perillyl alcohol or iso-perillyl alcohol. The present methods also treat neurofibromatosis by administering to a subject a carbamate of perillyl alcohol, or a carbamate of iso-perillyl alcohol. The perillyl alcohol carbamate may comprise perillyl alcohol conjugated with rolipram or temozolomide.

公开(公告)号：US20170297985A1

公开(公告)日：2017-10-19

申请号：US15639700

申请日：2017-06-30

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN

IPC: C07C33/14 ,  C07D231/12 ,  C07D207/26 ,  A61K45/06 ,  A61K31/045 ,  A61N5/10 ,  A61K31/495 ,  A61K31/4188 ,  A61K31/415 ,  A61K31/4015 ,  C07D487/04 ,  C07B59/00 ,  C07C2601/16

CPC classification number: C07C33/14 ,  A61K31/045 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4188 ,  A61K31/495 ,  A61K31/635 ,  A61K45/06 ,  A61K47/54 ,  A61K47/55 ,  A61N5/10 ,  A61N2005/1098 ,  C07D207/26 ,  C07D231/12 ,  C07D487/04

Abstract: The present methods treat neurofibromatosis by administering to a subject perillyl alcohol or iso-perillyl alcohol The present methods also treat neurofibromatosis by administering to a subject a carbamate of perillyl alcohol, or a carbamate of iso-perillyl alcohol The perillyl alcohol carbamate may comprise perillyl alcohol conjugated with rolipram or temozolomide.

公开(公告)号：US20170128578A1

公开(公告)日：2017-05-11

申请号：US15291847

申请日：2016-10-12

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPALLI

IPC: A01N43/52 ,  A61K45/06 ,  C07D231/12 ,  C07D487/04 ,  A61K31/4015 ,  C07D207/26 ,  A61K31/415 ,  A61K31/495

CPC classification number: A61K31/495 ,  A61K9/0043 ,  A61K31/045 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4188 ,  A61K45/06 ,  A61K47/54 ,  A61K47/542 ,  A61K47/543 ,  A61N5/10 ,  C07B59/00 ,  C07B2200/05 ,  C07C33/14 ,  C07C2601/16 ,  C07D207/26 ,  C07D231/12 ,  C07D487/04

Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

公开(公告)号：US20170119758A1

公开(公告)日：2017-05-04

申请号：US15408866

申请日：2017-01-18

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPALLI

IPC: A61K31/495 ,  A61K9/00 ,  A61N5/10 ,  A61K45/06

CPC classification number: C07C33/14 ,  A61K9/0043 ,  A61K31/045 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4188 ,  A61K31/495 ,  A61K45/06 ,  A61K47/54 ,  A61K47/542 ,  A61K47/543 ,  A61N5/10 ,  C07B59/00 ,  C07B2200/05 ,  C07C2601/16 ,  C07D207/26 ,  C07D231/12 ,  C07D487/04

Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene for sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

公开(公告)号：US20170088494A1

公开(公告)日：2017-03-30

申请号：US15285172

申请日：2016-10-04

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN

IPC: C07C29/92 ,  C07C29/86 ,  C07C29/78

CPC classification number: C07C29/92 ,  A61K31/045 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07B2200/07 ,  C07C29/78 ,  C07C29/86 ,  C07C29/88 ,  C07C67/14 ,  C07C201/12 ,  C07C201/16 ,  C07C2601/16 ,  C07C33/14 ,  C07C205/57 ,  C07C69/76 ,  C07C69/92

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.